Ironwood Investment Counsel LLC Acquires Shares of 677 Cencora, Inc. $COR

Ironwood Investment Counsel LLC acquired a new position in shares of Cencora, Inc. (NYSE:COR) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 677 shares of the company’s stock, valued at approximately $203,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC raised its position in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares in the last quarter. Costello Asset Management INC acquired a new stake in Cencora in the first quarter worth about $28,000. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Cencora during the first quarter worth about $39,000. Hantz Financial Services Inc. increased its holdings in shares of Cencora by 712.0% during the second quarter. Hantz Financial Services Inc. now owns 203 shares of the company’s stock valued at $61,000 after acquiring an additional 178 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Cencora in the 2nd quarter valued at approximately $61,000. 97.52% of the stock is currently owned by institutional investors.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 41,544 shares of company stock worth $12,230,941 over the last 90 days. 10.80% of the stock is currently owned by company insiders.

Cencora Trading Down 0.4%

Shares of Cencora stock opened at $363.75 on Thursday. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $366.17. The firm has a market capitalization of $70.52 billion, a PE ratio of 37.42, a P/E/G ratio of 1.56 and a beta of 0.63. The firm’s 50-day moving average price is $318.52 and its 200 day moving average price is $301.12.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date is Friday, November 14th. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on COR shares. Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a research note on Thursday, October 30th. Wall Street Zen raised Cencora from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. UBS Group upped their target price on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Morgan Stanley set a $330.00 price objective on Cencora and gave the stock an “equal weight” rating in a research report on Wednesday, July 16th. Finally, TD Cowen upped their price objective on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $371.09.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.